Phase I Study of NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma, for Whom Treatment With Ipilimumab is Indicated

This was a Phase 1, open-label, non-randomized study of the combination of NY-ESO-1 plus ipilimumab in patients with unresectable or metastatic melanoma for whom treatment with ipilimumab was indicated. Patients must have had evidence of NY-ESO-1 or LAGE-1 tumor positivity and radiologically measurable disease by the immune-related Response Criteria (irRC). Primary study objectives were to determine the safety and tolerability of the combination and to evaluate humoral and cellular immune response. Secondary objectives were to evaluate tumor response and immunological changes in the tumor microenvironment.

开始日期2014-01-24

申办/合作机构

Ludwig Institute for Cancer Research Ltd.

NCT00616941 / Completed临床1期IIT

A Phase 1 Study of NY-ESO-1 Overlapping Peptides With or Without Immunoadjuvants Montanide and Poly-ICLC Vaccination of Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer Patients in Second or Third Remission

This was a Phase 1, open-label study of repeated vaccination with NY-ESO-1 overlapping peptides (OLP4) with or without the immunoadjuvants Montanide and polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose (poly-ICLC) administered every 3 weeks for a total of 5 vaccinations in subjects with epithelial ovarian, fallopian tube, or primary peritoneal cancer in second or third clinical remission. Study objectives included determination of the safety and immunogenicity following vaccination.

开始日期2008-03-01

申办/合作机构

Ludwig Institute for Cancer Research Ltd.

[+1]

NCT00112957 / Completed临床2期IIT

Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen

This was a Phase 2, single-center, open-label study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) injections in patients who had a complete response to standard therapy for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and whose tumors expressed NY-ESO-1 or LAGE-1 antigen. Study objectives were to evaluate maintenance of remission at 12 months, time to failure of vaccine therapy, cellular and humoral immunity and any correlation with time to failure, and safety.

开始日期2004-12-01

申办/合作机构

Ludwig Institute for Cancer Research Ltd.

[+1]

100 项与 NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center) 相关的临床结果

登录后查看更多信息

100 项与 NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center) 相关的转化医学

登录后查看更多信息

100 项与 NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center) 相关的专利（医药）

登录后查看更多信息

100 项与 NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
输卵管癌	临床1期	美国	Ludwig Institute for Cancer Research Ltd.	2008-03-31
卵巢上皮癌	临床1期	美国	Ludwig Institute for Cancer Research Ltd.	2008-03-31
原发性腹膜癌	临床1期	美国	Ludwig Institute for Cancer Research Ltd.	2008-03-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01810016 (P366, CTgov)	临床1期	不可切除的黑色素瘤	8	Arm A (Arm A (Ipi, NY-ESO-1 Protein))	蓋鑰淵憲鏇膚鏇齋夢膚(鹽鑰遞遞積艱醖窪願築) = 襯鏇糧淵鹽膚選顧窪範醖淵艱鏇選廠衊積蓋淵 (鏇鑰鑰積觸繭獵齋積壓, 積製艱獵壓構窪醖鬱壓 ~ 築願膚鑰餘壓齋遞鏇鑰) 更多	-	2018-11-30
				Ipi+NY-ESO-1 OLP4 (Arm B (Ipi, NY-ESO-1 OLP4))	蓋鑰淵憲鏇膚鏇齋夢膚(鹽鑰遞遞積艱醖窪願築) = 淵衊積鹽選夢齋鑰選壓醖淵艱鏇選廠衊積蓋淵 (鏇鑰鑰積觸繭獵齋積壓, 遞蓋鬱襯構憲齋範鹹鏇 ~ 鑰選鏇膚積艱構築範築) 更多
NCT00616941 (CTgov)	临床1期	原发性腹膜癌 \| 卵巢上皮癌 \| 输卵管癌	28	NY-ESO-1 OLP4 (Cohort 1)	淵糧膚鑰鑰衊襯膚鑰構(繭範襯餘獵鹽鬱淵鬱衊) = 積憲願製網憲鹽鹹膚糧獵構顧夢繭簾繭願壓窪 (觸鏇壓鏇獵鏇醖積築鑰, 顧遞遞簾鏇餘壓積糧獵 ~ 鑰鹹鏇遞蓋鏇窪窪鏇鬱) 更多	-	2018-07-27
				NY-ESO-1 OLP4 + Montanide (Cohort 2)	淵糧膚鑰鑰衊襯膚鑰構(繭範襯餘獵鹽鬱淵鬱衊) = 艱願蓋範願窪製選襯糧獵構顧夢繭簾繭願壓窪 (觸鏇壓鏇獵鏇醖積築鑰, 醖衊獵遞壓夢窪蓋廠衊 ~ 鏇繭窪齋糧顧醖獵網願) 更多
NCT00112957 (CTgov)	临床2期	原发性腹膜癌 \| 卵巢癌 \| 输卵管癌	23	rV-NY-ESO-1 vaccine	鹽糧艱齋鑰窪鑰襯鹹繭(夢範齋網製醖製壓範衊) = 糧積遞壓鏇壓鏇膚糧繭鹹廠遞鏇憲願窪鹹遞築 (構醖艱餘鑰顧衊淵蓋選, 獵遞鏇廠選醖構壓積簾 ~ 壓廠壓衊鏇顧鑰壓襯繭) 更多	-	2018-03-19